Silodosin vs Tamsulosin as MET
Launched by PRINCESS MARGARET HOSPITAL, HONG KONG · Oct 3, 2022
Trial Information
Current as of May 06, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Presented with radio-opaque ureteric stone of size 5mm to 10mm on KUB
- • Patients who can understand the study protocol and comply with the followup schedule
- Exclusion criteria:
- • Radiolucent stone
- • Paper thin cortex
- • Non-functioning kidney
- • Renal insufficiency (serum creatinine greater than 1.8 mg/dl or 160umol/dL)
- • Concurrent urosepsis
- • Current \[alpha\]-blocker usage, Ca channel blocker, steroid
- • Pregnancy
- • Age \< 18
- • History of ureteral stricture
- • History of ureteric stone treatment within 2 years
- • Allergic reaction to the study medication
- • Unable to Consent
- • Patient on JJ stent or PCN drainage
About Princess Margaret Hospital, Hong Kong
Princess Margaret Hospital in Hong Kong is a leading healthcare institution renowned for its commitment to advanced cancer care and innovative research. As a prominent clinical trial sponsor, the hospital focuses on developing and evaluating new therapeutic strategies to improve patient outcomes in oncology. With a multidisciplinary team of experts and state-of-the-art facilities, Princess Margaret Hospital actively engages in cutting-edge clinical trials, fostering collaboration with international research networks to contribute to the global fight against cancer. Its dedication to patient-centered care and scientific excellence positions it at the forefront of clinical research in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials